Department of Life Sciences and Biotechnology, University of Ferrara, Italy.
Int J Pharm. 2013 Oct 1;454(2):695-702. doi: 10.1016/j.ijpharm.2013.06.015. Epub 2013 Jun 21.
The aim of the present work is to design a new formulation containing clotrimazole (CTZ) loaded into nanostructured lipid carriers (NLC) for the treatment of fungal vaginal infections. In order to obtain formulations with suitable viscosity for mucosal application, NLC containing CTZ produced by the ultrasonication method were viscosized by the addition of poloxamer P407 in the NLC dispersion (CTZ-NLC-gel). These systems exhibit well-known thermogelling properties. The rheological characterization of the CTZ-NLC hydrogel using a controlled stress rheometer evidenced that the presence of NLC or CTZ did not affect gelling temperature (Tgel). Dilution with simulated vaginal fluid (SVF) increased the Tgel from 17.4 to 29.6°C. For these thermogelling systems, micro-calorimetric assays conducted by a Micro-DSC III confirmed that the hydrogel-containing CTZ-NLC was able to change its structure with a rapid passage from non-crystalline (liquid) to crystalline (semi-solid) form. Furthermore, when a local application is considered, no drug should pass through the vaginal mucosa, limiting thus the systemic diffusion and toxicity. For this purpose, Franz cell has been employed to investigate the ex vivo permeation of CTZ through pig vaginal mucosa. The results showed no CTZ diffusion. The toxicological experiments performed on HeLa cells after a 24h incubation time confirmed that CTZ-NLC-gel at a concentration of 1mg/mL showed a low toxicity profile resulting in a cell vitality of 77.2%. Interestingly, anti-candida activity studies demonstrated that CTZ-NLC gel was 4-fold more active than Fungizone(®) against Candida albicans. These encouraging results suggest that the hydrogel containing CTZ-NLC could be proposed as an innovative system to administer CTZ to treat vaginal infections.
本工作旨在设计一种含有克霉唑(CTZ)的新型制剂,将其载入纳米结构脂质载体(NLC),用于治疗真菌性阴道感染。为了获得适用于黏膜应用的粘性制剂,通过在 NLC 分散体(CTZ-NLC-凝胶)中加入泊洛沙姆 P407,使通过超声法制备的载 CTZ 的 NLC 增粘(CTZ-NLC-凝胶)。这些系统表现出众所周知的温敏凝胶特性。使用控制应变速率流变仪对 CTZ-NLC 水凝胶的流变特性进行表征,结果表明 NLC 或 CTZ 的存在并不影响凝胶化温度(Tgel)。用模拟阴道液(SVF)稀释使 Tgel 从 17.4°C 增加到 29.6°C。对于这些温敏凝胶系统,通过 Micro-DSC III 进行的微量量热法测定证实,载 CTZ 的 NLC 水凝胶能够快速从非晶(液体)态转变为结晶(半固体)态,从而改变其结构。此外,当考虑局部应用时,不应有药物通过阴道黏膜,从而限制了药物的全身扩散和毒性。为此,采用 Franz 细胞研究了 CTZ 通过猪阴道黏膜的体外渗透。结果表明没有 CTZ 扩散。在 24 小时孵育时间后对 HeLa 细胞进行的毒理学实验证实,浓度为 1mg/mL 的 CTZ-NLC-凝胶表现出低毒性,细胞活力为 77.2%。有趣的是,抗念珠菌活性研究表明,CTZ-NLC 凝胶对白色念珠菌的活性比 Fungizone(®)高 4 倍。这些令人鼓舞的结果表明,载 CTZ 的 NLC 水凝胶可作为一种新型系统,用于管理 CTZ 治疗阴道感染。